1
|
Chaudhuri SE, Ben Chaouch Z, Hauber B, Mange B, Zhou M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Caldwell B, Benz HL, Ho M, Saha A, Gwinn K, Sheldon M, Lo AW. Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson's disease. J Biopharm Stat 2023:1-20. [PMID: 36861942 DOI: 10.1080/10543406.2023.2170400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 01/15/2023] [Indexed: 03/03/2023]
Abstract
A fixed one-sided significance level of 5% is commonly used to interpret the statistical significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive rate, the threshold used could be chosen quantitatively and transparently to specifically reflect patient preferences regarding benefit-risk tradeoffs as well as other considerations. How can patient preferences be explicitly incorporated into RCTs in Parkinson's disease (PD), and what is the impact on statistical thresholds for device approval? In this analysis, we apply Bayesian decision analysis (BDA) to PD patient preference scores elicited from survey data. BDA allows us to choose a sample size (n ) and significance level (α ) that maximizes the overall expected value to patients of a balanced two-arm fixed-sample RCT, where the expected value is computed under both null and alternative hypotheses. For PD patients who had previously received deep brain stimulation (DBS) treatment, the BDA-optimal significance levels fell between 4.0% and 10.0%, similar to or greater than the traditional value of 5%. Conversely, for patients who had never received DBS, the optimal significance level ranged from 0.2% to 4.4%. In both of these populations, the optimal significance level increased with the severity of the patients' cognitive and motor function symptoms. By explicitly incorporating patient preferences into clinical trial designs and the regulatory decision-making process, BDA provides a quantitative and transparent approach to combine clinical and statistical significance. For PD patients who have never received DBS treatment, a 5% significance threshold may not be conservative enough to reflect their risk-aversion level. However, this study shows that patients who previously received DBS treatment present a higher tolerance to accept therapeutic risks in exchange for improved efficacy which is reflected in a higher statistical threshold.
Collapse
Affiliation(s)
- Shomesh E Chaudhuri
- Laboratory for Financial Engineering, MIT Sloan School of Management, Cambridge, MA, USA
| | - Zied Ben Chaouch
- Laboratory for Financial Engineering, MIT Sloan School of Management, Cambridge, MA, USA
- Electrical Engineering and Computer Science Department, MIT, Cambridge, MA, USA
| | - Brett Hauber
- RTI Health Solutions, Research Triangle Park, NC, USA
- CHOICE Institute, University of Washington School of Pharmacy, Seattle, WA, USA
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, NC, USA
| | - Mo Zhou
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | | | - Dawn Bardot
- Medical Device Innovation Consortium, Arlington, VA, USA
| | - Margaret Sheehan
- Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
| | - Anne Donnelly
- Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
| | - Lauren McLaughlin
- Strategy and Planning, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
| | - Brittany Caldwell
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Heather L Benz
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Martin Ho
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Anindita Saha
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Katrina Gwinn
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Murray Sheldon
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
| | - Andrew W Lo
- Laboratory for Financial Engineering, MIT Sloan School of Management, Cambridge, MA, USA
- Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA
- Santa Fe Institute, Santa Fe, NM, USA
| |
Collapse
|
2
|
Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient Prefer Adherence 2022; 16:573-585. [PMID: 35256844 PMCID: PMC8898176 DOI: 10.2147/ppa.s345906] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Accepted: 02/19/2022] [Indexed: 01/28/2023] Open
Abstract
INTRODUCTION/BACKGROUND This study aimed to describe patient and caregiver preferences for treatments of relapsed or refractory multiple myeloma (MM). MATERIALS AND METHODS A survey including discrete-choice experiment (DCE) and best-worst scaling (BWS) exercises was conducted among US patients with relapsed or refractory MM and their caregivers. The DCE included six attributes with varying levels including progression-free survival (PFS), toxicity, and mode and frequency of administration. In addition, the impact of treatment cost was assessed using a fixed-choice question. The BWS exercise included 18 items (modes and frequency of administration, additional treatment convenience, and toxicity items). The survey was administered online to patients recruited from the Multiple Myeloma Research Foundation CoMMpass study (NCT01454297). RESULTS The final samples consisted of 94 patients and 32 caregivers. Avoiding severe nerve damage was most important to patients, followed by longer PFS. Caregivers considered PFS to be the most important attribute. We estimate that a third or more of patients were cost-sensitive, meaning their treatment preference was altered based on cost implications. Caregivers were not cost-sensitive. The three most bothersome treatment features in the BWS exercise were risk of kidney failure, lowering white blood cell counts, and weakening the immune system. CONCLUSION Patients with relapsed or refractory MM and their caregivers consider many factors including efficacy, toxicity, mode/frequency of administration, and cost in their decisions regarding treatment options. The study provides a basis for future Research on patient and caregiver treatment preferences, which could be incorporated into shared decision-making with physicians.
Collapse
Affiliation(s)
- Daniel Auclair
- Department of Research, Multiple Myeloma Research Foundation, Norwalk, CT, USA
- Correspondence: Daniel Auclair, AstraZeneca Oncology R&D| Hematology, 35 Gatehouse Drive, Waltham, MA, 02451, USA, Email
| | | | - Mark A Fiala
- Division of Hematology & Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Ajai Chari
- Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA
| | - Craig E Cole
- Department of Medicine, MSU Breslin Cancer Center, Lansing, MI, USA
| | - Jonathan L Kaufman
- Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
| | | | - David S Siegel
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
| | - Jeffrey A Zonder
- Division of Clinical Hematology-Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, NC, USA
| | - Jennifer Yesil
- Department of Research, Multiple Myeloma Research Foundation, Norwalk, CT, USA
| | - Mehul Dalal
- Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical, Company Ltd, Cambridge, MA, USA
| | - Joseph R Mikhael
- Translational Genomic Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA
| |
Collapse
|
3
|
Patterson BJ, Myers K, Stewart A, Mange B, Hillson EM, Poulos C. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. Expert Rev Vaccines 2021; 20:729-741. [PMID: 33902368 DOI: 10.1080/14760584.2021.1910502] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Most adults, and disproportionately fewer African-Americans, have not received herpes zoster (HZ) vaccination despite current recommendations. This study (GSK study identifiers: 208677/HO-17-18066) assessed HZ vaccination preferences among adults aged ≥ 50 years. RESEARCH DESIGN AND METHODS In this discrete choice experiment, respondents chose among a 'no vaccine' option and two HZ vaccine profiles, characterized by seven attributes, in a series of choice questions. Random-parameters logit results were used to predict likely vaccine uptake. Subgroup and latent class analysis of African-American's preferences were performed. RESULTS The preference weight for choosing HZ vaccines over no vaccine was statistically significant among the 1,454 respondents (71.9% whites; 25.2% African-Americans). Out-of-pocket (OOP) cost and vaccine effectiveness (VE) were the most important attributes. The African-American and the non-African-American subgroups had statistically significant differences in preferences (χ2 = 59.91, p < 0.001), mainly driven by OOP cost and VE. Latent class analysis identified three groups of African-American respondents with systematically different preferences; two comprised likely-vaccinators, with one being more cost sensitive at lower price thresholds, and one likely non-vaccinators. CONCLUSIONS For all respondents, HZ vaccine choices were most sensitive to total OOP cost, followed by VE.
Collapse
Affiliation(s)
| | - Kelley Myers
- Health Preference Assessment Group, RTI Health Solutions, Research Triangle Park, NC, United States
| | | | - Brennan Mange
- Health Preference Assessment Group, RTI Health Solutions, Research Triangle Park, NC, United States
| | - Eric M Hillson
- US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, United States
| | - Christine Poulos
- Health Preference Assessment Group, RTI Health Solutions, Research Triangle Park, NC, United States
| |
Collapse
|
4
|
Benz HL, Caldwell B, Ruiz JP, Saha A, Ho M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Mange B, Hauber AB, Gwinn K, Heetderks WJ, Sheldon M. Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease. MDM Policy Pract 2021; 6:23814683211021380. [PMID: 34277950 PMCID: PMC8255597 DOI: 10.1177/23814683211021380] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Accepted: 04/30/2021] [Indexed: 11/16/2022] Open
Abstract
Introduction. A growing literature has developed on identifying outcomes that matter to patients. This study demonstrates an approach involving patient and regulatory perspectives to identify outcomes that are meaningful in the context of medical devices for Parkinson’s disease (PD). Methods. A systematic process was used for specifying relevant regulatory endpoints by synthesizing inputs of various sources and stakeholders. First, a literature review was conducted to identify important benefits, risks, and other considerations for medical devices to treat PD; patient discussion groups (n = 6) were conducted to refine the list of considerations, followed by a survey (n = 29) to prioritize them; and patient and Food and Drug Administration (FDA) reviewers informed specification of the final endpoints. Two FDA clinicians gave clinical and regulatory perspectives at each step. Results. Movement symptoms were ranked as most important (ranked 1 or 2 by 72% of participants) and psychological and cognitive symptoms as the next most important (ranked 1 or 2 by 52% of participants). Within movement symptoms, falls, impaired movement, bradykinesia, resting tremor, stiffness, and rigidity were ranked highly. Overall, nine attributes were identified and prioritized as patient-centric for use in clinical trial design and quantitative patient preference studies. These attributes were benefits and risks related to therapeutics for PD as well as other considerations, including time until a medical device is available for patient use. Discussion. This prospective approach identified meaningful and relevant benefits, risks, and other considerations that may be used for clinical trial design and quantitative patient preference studies. Although PD was the focus of this study, the approach can be used to study patient perspectives about other disease or treatment areas.
Collapse
Affiliation(s)
- Heather L Benz
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Brittany Caldwell
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - John P Ruiz
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Anindita Saha
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Martin Ho
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | | | - Dawn Bardot
- Medical Device Innovation Consortium, Arlington, Virginia
| | - Margaret Sheehan
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York
| | - Anne Donnelly
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York
| | - Lauren McLaughlin
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, North Carolina
| | - A Brett Hauber
- RTI Health Solutions, Research Triangle Park, North Carolina
| | - Katrina Gwinn
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | | | - Murray Sheldon
- US FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| |
Collapse
|
5
|
Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med 2021; 9:e1664. [PMID: 33755338 PMCID: PMC8172191 DOI: 10.1002/mgg3.1664] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 02/17/2021] [Accepted: 02/18/2021] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Gene therapy offers an etiologically targeted treatment for genetic disorders. Little is known about the acceptance of mortality risk among patients with progressive, fatal conditions. We assessed patients' and caregivers' maximum acceptable risk (MAR) of mortality for gene therapy when used to treat Duchenne muscular dystrophy (DMD). METHODS The threshold technique was used to assess tolerance for mortality risks using a hypothetical vignette. Gene therapy was described as non-curative and resulting in a slowing of progression and with a 10-year benefit duration. MAR was analyzed using interval regression for gene therapy initiated "now"; in the last year of walking well; in the last year of being able to bring arms to mouth; and in newborns (for caregivers only). RESULTS Two hundred eighty-five caregivers and 35 patients reported the greatest MAR for gene therapy initiated in last year of being able to lift arms (mean MAR 6.3%), followed by last year of walking well (mean MAR 4.4%), when used "now" (mean MAR 3.5%), and when used in the newborn period (mean MAR 2.1%, caregivers only). About 35% would accept ≥200/2000 risk in the last year of being able to lift arms. Non-ambulatory status predicted accepting 1.8 additional points in MAR "now" compared with ambulatory status (p = 0.010). Respondent type (caregiver or patient) did not predict MAR. CONCLUSION In this first quantitative study to assess MAR associated with first-generation DMD gene therapy, we find relatively high tolerance for mortality risk in response to a non-curative treatment scenario. Risk tolerance increased with disease progression. Patients and caregivers did not have significantly different MAR. These results have implications for protocol development and shared decision making.
Collapse
Affiliation(s)
- Holly L Peay
- RTI International, Research Triangle Park, NC, USA
| | - Ryan Fischer
- Parent Project Muscular Dystrophy, Hackensack, NJ, USA
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, NC, USA
| | | | | | | | | | | | - Colin Rensch
- Parent Project Muscular Dystrophy, Hackensack, NJ, USA
| | | | | | | | | | | |
Collapse
|
6
|
Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J DERMATOL TREAT 2021; 33:1511-1520. [PMID: 33535847 DOI: 10.1080/09546634.2020.1839007] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. OBJECTIVE Determine attributes of biologic psoriasis treatments that drive patients' treatment choices. METHODS Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice-experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. RESULTS U.S. respondents most valued clear skin (conditional relative importance, 1.88; p < .05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p < .05). German respondents placed greatest importance on ISR risk (1.61; p < .05) and clear skin (1.49; p < .05). LIMITATIONS Respondents evaluated hypothetical treatments and were recruited from web panels. CONCLUSIONS Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.
Collapse
Affiliation(s)
- Steven R Feldman
- Departmemt of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | | | | | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, NC, USA
| | | | | | - Mandy Naatz
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Matthias Augustin
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
7
|
Hauber B, Mange B, Zhou M, Chaudhuri S, Benz HL, Caldwell B, Ruiz JP, Saha A, Ho M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Gwinn K, Lo A, Sheldon M. Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM Policy Pract 2021; 6:2381468320978407. [PMID: 33521289 PMCID: PMC7818008 DOI: 10.1177/2381468320978407] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 10/28/2020] [Indexed: 11/25/2022] Open
Abstract
Background. Parkinson’s disease (PD) is neurodegenerative, causing
motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding
PD patients’ preferences for novel neurostimulation devices may help ensure that
devices are delivered in a timely manner with the appropriate level of evidence.
Our objective was to elicit preferences and willingness-to-wait for novel
neurostimulation devices among PD patients to inform a model of optimal trial
design. Methods. We developed and administered a survey to PD
patients to quantify the maximum levels of risks that patients would accept to
achieve potential benefits of a neurostimulation device. Threshold technique was
used to quantify patients’ risk thresholds for new or worsening depression or
anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor
symptoms, pain, cognition, and pill burden. The survey elicited patients’
willingness to wait to receive treatment benefit. Patients were recruited
through Fox Insight, an online PD observational study. Results. A
total of 2740 patients were included and a majority were White (94.6%) and had a
4-year college degree (69.8%). Risk thresholds increased as benefits increased.
Threshold for depression or anxiety was substantially higher than threshold for
brain bleed or death. Patient age, ambulation, and prior neurostimulation
experience influenced risk tolerance. Patients were willing to wait an average
of 4 to 13 years for devices that provide different levels of benefit.
Conclusions. PD patients are willing to accept substantial
risks to improve symptoms. Preferences are heterogeneous and depend on treatment
benefit and patient characteristics. The results of this study may be useful in
informing review of device applications and other regulatory decisions and will
be input into a model of optimal trial design for neurostimulation devices.
Collapse
Affiliation(s)
- Brett Hauber
- RTI Health Solutions, Research Triangle Park, North Carolina
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, North Carolina
| | - Mo Zhou
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | | | - Heather L Benz
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Brittany Caldwell
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - John P Ruiz
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Anindita Saha
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Martin Ho
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | | | - Dawn Bardot
- Medical Device Innovation Consortium, Arlington, Virginia
| | - Margaret Sheehan
- The Michael J. Fox Foundation for Parkinson's Research, Patient Council, New York, New York
| | - Anne Donnelly
- The Michael J. Fox Foundation for Parkinson's Research, Patient Council, New York, New York
| | - Lauren McLaughlin
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York
| | - Katrina Gwinn
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| | - Andrew Lo
- MIT Sloan School of Management, Cambridge, Massachusetts
| | - Murray Sheldon
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland
| |
Collapse
|
8
|
Browne EN, Montgomery ET, Mansfield C, Boeri M, Mange B, Beksinska M, Schwartz JL, Clark MR, Doncel GF, Smit J, Chirenje ZM, van der Straten A. Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. AIDS Behav 2020; 24:1443-1451. [PMID: 31696371 PMCID: PMC6990865 DOI: 10.1007/s10461-019-02715-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
As new female-initiated HIV prevention products enter development, it is crucial to incorporate women’s preferences to ensure products will be desired, accepted, and used. A discrete-choice experiment was designed to assess the relative importance of six attributes to stated choice of a vaginally delivered HIV prevention product. Sexually active women in South Africa and Zimbabwe aged 18–30 were recruited from two samples: product-experienced women from a randomized trial of four vaginal placebo forms and product-naïve community members. In a tablet-administered survey, 395 women chose between two hypothetical products over eight choice sets. Efficacy was the most important, but there were identifiable preferences among other attributes. Women preferred a product that also prevented pregnancy and caused some wetness (p < 0.001). They disliked a daily-use product (p = 0.002) and insertion by finger (p = 0.002). Although efficacy drove preference, wetness, pregnancy prevention, and dosing regimen were influential to stated choice of a product, and women were willing to trade some level of efficacy to have other more desired attributes.
Collapse
Affiliation(s)
- Erica N Browne
- Women's Global Health Imperative, RTI International, 351 California Street, Suite 500, San Francisco, CA, 94104, USA.
| | - Elizabeth T Montgomery
- Women's Global Health Imperative, RTI International, 351 California Street, Suite 500, San Francisco, CA, 94104, USA
| | - Carol Mansfield
- Health Solutions, RTI International, Research Triangle Park, NC, USA
| | - Marco Boeri
- Health Solutions, RTI International, Research Triangle Park, NC, USA
| | - Brennan Mange
- Health Solutions, RTI International, Research Triangle Park, NC, USA
| | - Mags Beksinska
- MatCH Research Unit (MRU), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa
| | | | | | | | - Jenni Smit
- MatCH Research Unit (MRU), Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa
| | - Zvavahera M Chirenje
- University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe
| | - Ariane van der Straten
- Women's Global Health Imperative, RTI International, 351 California Street, Suite 500, San Francisco, CA, 94104, USA
- Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, CA, USA
| |
Collapse
|
9
|
Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Mult Scler J Exp Transl Clin 2020; 6:2055217320910778. [PMID: 32215218 PMCID: PMC7065293 DOI: 10.1177/2055217320910778] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Accepted: 01/21/2020] [Indexed: 11/26/2022] Open
Abstract
Objective To assess heterogeneity in patient and physician preferences for multiple sclerosis treatment features and outcomes via a discrete-choice experiment. Method Patients with self-reported multiple sclerosis and treating physicians participated in an online discrete-choice experiment. Patients, each considering a better or worse reference condition, and physicians, each considering two patient profiles, chose between hypothetical treatment profiles defined by seven attributes with varying levels: years until disability progression, number of relapses in the decade, mode of administration, dosing frequency, and risks of mild, moderate, and severe side effects. Latent class analysis was used to measure respondent preferences and identify potential subgroups with distinct preferences. Results Distinct treatment preferences emerged among subgroups of patients (n = 301) and physicians (n = 308). Patients in class 1 (43% of sample) were most concerned about side effects; chief concerns of class 2 patients (57%) were delaying disability progression and avoiding severe side-effect risks. The most important attributes for physicians (by class) were delaying disability (class 1, 45%), avoiding severe side-effect risks and (class 2, 33%), and avoiding all side-effect risks (class 3, 22%). Conclusion Patients and physicians have diverse preferences for multiple sclerosis treatments, reflecting heterogeneity in the disease course and available therapies and the need for shared decision making.
Collapse
|
10
|
Poulos C, Wakeford C, Kinter E, Mange B, Schenk T. PND16 PREFERENCES OF PATIENTS FOR FEATURES OF INJECTABLE, ORAL, AND INFUSED DISEASE-MODIFYING TREATMENTS FOR RELAPSE-REMITTING MULTIPLE SCLEROSIS. Value Health Reg Issues 2019. [DOI: 10.1016/j.vhri.2019.08.346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Boeri M, Szegvari B, Hauber B, Mange B, Mountian I, Schiff M, Maniadakis N. From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices. Patient Prefer Adherence 2019; 13:1093-1110. [PMID: 31371927 PMCID: PMC6636455 DOI: 10.2147/ppa.s203775] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 06/08/2019] [Indexed: 12/02/2022] Open
Abstract
PURPOSE To quantify rheumatology patient preferences and willingness to pay (WTP) for features differentiating enhanced from standard self-injection devices and to investigate differences among subgroups. PATIENTS AND METHODS Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) were recruited in the UK. A discrete-choice experiment was used to elicit preferences; respondents were presented with 10 choices between 3 different devices: a free standard disposable device, and 2 hypothetical reusable devices characterized by presence/absence of skin sensor, injection speed control, on-screen instructions, injection reminders, electronic log, and large grip. Every hypothetical device included a cost component to assess WTP for each enhanced feature. A random-parameters logit model was used to estimate preference weights and WTP. RESULTS Data were collected from 323 respondents by electronic survey (15/11/2017-15/02/2018; RA: 108; PsA: 103; axSpA: 112). On average, the skin sensor was the most preferred feature (£30), followed by injection speed control, injection reminders, electronic log (~£20 each), on-screen instructions (~£12), and a device with a small, rather than large grip (~£7). Similar preferences for attributes were observed across condition subgroups except for grip size: axSpA patients preferred small grip (~£27); PsA patients preferred large grip (~£19). Overall, respondents preferred reusable devices with all enhanced features (WTP value: £85) over the standard device. RA patients exhibited a higher WTP (£145) than PsA (£102) or axSpA (£62) for the same enhanced device. CONCLUSION Patients positively valued reusable self-injection devices with enhanced features, which may improve patient experience, potentially improving treatment adherence, clinical, and economic outcomes.
Collapse
Affiliation(s)
| | | | - Brett Hauber
- RTI Health Solutions
, Research Triangle Park, NC, USA
| | - Brennan Mange
- RTI Health Solutions
, Research Triangle Park, NC, USA
| | | | - Michael Schiff
- Rheumatology Division, University of Colorado School of Medicine, Denver, CO, USA
| | - Nikolaos Maniadakis
- Health Services Management, National School of Public Health, Athens, Greece
| |
Collapse
|
12
|
Dawson K, Mange B, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Price M, Mansfield C, Comenencia-Ortíz E, Masaquel A, Ravelo A. PATIENT-REPORTED EXPERIENCE AND PREFERENCES WITH TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL). Hematol Oncol 2019. [DOI: 10.1002/hon.225_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- K. Dawson
- US Medical Affairs, Genentech, Inc.; South San Francisco CA United States
| | - B. Mange
- Health Preference Assessment; RTI Health Solutions, Research Triangle Park; NC United States
| | - P. A. Torney
- Education and Support Services; Lymphoma Research Foundation; New York NY United States
| | - V. Gonzalez
- Support Services; Lymphoma Research Foundation; New York NY United States
| | - M. Sae-Hau
- Patient Access; The Leukemia & Lymphoma Society; Rye Brook NY United States
| | - E. Weiss
- Patient Access; The Leukemia & Lymphoma Society; Rye Brook NY United States
| | - M. Price
- Surveys and Observational Studies; RTI Health Solutions, Research Triangle Park; NC United States
| | - C. Mansfield
- Health Preference Assessment; RTI Health Solutions, Research Triangle Park; NC United States
| | - E. Comenencia-Ortíz
- Alliance & Advocacy Relations, Genentech, Inc.; South San Francisco CA United States
| | - A. Masaquel
- US Medical Affairs, Genentech, Inc.; South San Francisco CA United States
| | - A. Ravelo
- US Medical Affairs, Genentech, Inc.; South San Francisco CA United States
| |
Collapse
|
13
|
Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Dawson KL. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: Results from a national patient advocacy survey. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e18198] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18198 Background: Evaluations of patients’ (pt) burden and priorities are increasingly important as novel treatments are developed. We aimed to better understand pt-reported disease burden in chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Methods: We developed a survey to understand pt disease burden, designed in consultation with medical experts, pt advocacy organizations, and survey scientists. Concept elicitation and cognitive pretesting were conducted. The survey was administered electronically to pts who had received either initial or subsequent treatment within the past year and consisted of categorical Likert options that quantified the impact of disease on physical function, sleep, cognition, work, emotional health, and quality of life (QoL). Results: The Leukemia & Lymphoma Society and the Lymphoma Research Foundation recruited 424 pts: 309 with CLL, 59 with DLBCL, and 69 with FL; 51% were female. Mean age was 66 (range: 22–95). Results suggest that pts experience substantial disease burden across all surveyed subtypes. The most noteworthy results are highlighted in the following table that indicates the percentage of pts who agreed or strongly agreed to statements about disease burden. Additionally, large proportions of pts worried about their disease returning or getting worse (72% of pts with CLL, 83% of pts with DLBCL, and 79% of pts with FL), indicating high impact regardless of the indolent or aggressive nature of their disease. Most pts indicated that delaying disease progression was important to them (96% of pts with CLL, 96% of pts with DLBCL, and 92% of pts with FL). Employment status changed for 31% of pts who were working full or part time or on contract because of their diagnosis and treatment. Conclusions: Pts with CLL, DLBCL, and FL report experiencing substantial disease burden. Data from studies focusing on pt-reported disease burden can be used for education of the clinical community to address the key concerns of pts.[Table: see text]
Collapse
Affiliation(s)
- Mark Price
- RTI Health Solutions, Research Triangle Park, NC
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, Martin AS, Morris C, Rensch C, Ricotti V, Russo LJ, Sadosky A, Smith EC, Peay HL. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis 2019; 14:102. [PMID: 31072340 PMCID: PMC6509771 DOI: 10.1186/s13023-019-1069-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 04/17/2019] [Indexed: 01/14/2023] Open
Abstract
PURPOSE Several gene therapy trials for Duchenne muscular dystrophy initiated in 2018. Trial decision making is complicated by non-curative, time-limited benefits; the progressive, fatal course; and high unmet needs. Here, caregivers and patients prioritize factors influencing decision making regarding participation in early-phase gene therapy trials. METHODS We conducted a best-worst scaling experiment among U.S. caregivers and adults with Duchenne (N = 274). Participants completed 11 choice sets, choosing features they cared about most and least when deciding whether to participate in a hypothetical gene therapy trial. We analyzed the data using sequential conditional logistic regression. RESULTS Participants prioritized improved muscle function in trial decision making. Concerns about participation limiting later use of gene transfer and editing were also important, as were improved lung and heart function. Low risk of death fell near the middle. Participants cared least about muscle biopsies and potential for randomization to placebo. Adults with Duchenne and caregivers of non-ambulatory children significantly prioritized improved lung function compared to caregivers of ambulatory children. CONCLUSION Our data demonstrate prioritization of anticipated benefits and opportunity costs relative to potential harms and procedures in gene therapy trial decision making. Such data inform protocol development, education and advocacy efforts, and informed consent.
Collapse
Affiliation(s)
- Ryan S Paquin
- RTI International, Research Triangle Park, North Carolina, USA
| | - Ryan Fischer
- Parent Project Muscular Dystrophy, Hackensack, NJ, USA
| | - Carol Mansfield
- RTI Health Solutions, Research Triangle Park, North Carolina, USA
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, North Carolina, USA
| | | | | | | | | | - Colin Rensch
- Parent Project Muscular Dystrophy, Hackensack, NJ, USA
| | | | | | | | | | - Holly L Peay
- RTI International, Research Triangle Park, North Carolina, USA.
| |
Collapse
|
15
|
Benz HL, Caldwell B, Ruiz JP, Saha A, Ho M, Christopher S, Bardot D, Sheehan M, Donnelly AC, McLaughlin L, Mange B, Hauber B, Gwinn K, Sheldon M. Abstract #81: Improving Neurostimulation Clinical Trial Design with Patient Experience Data. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
16
|
Brett Hauber A, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer 2017; 26:251-260. [PMID: 28785862 DOI: 10.1007/s00520-017-3841-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Accepted: 07/24/2017] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Although clinical guidelines recommend administration of pegfilgrastim 1-4 days after a myelosuppressive chemotherapy cycle to decrease the incidence of febrile neutropenia (FN), some physicians administer pegfilgrastim on the same day as chemotherapy administration. A novel on-body injector (OBI) that automatically delivers pegfilgrastim the day after chemotherapy is also available. Our objective was to estimate patient and physician preferences among the pegfilgrastim administration options. METHODS We conducted a cross-sectional survey of patients receiving pegfilgrastim and physicians prescribing pegfilgrastim. Respondents' preferences for pegfilgrastim administration options were elicited using direct elicitation; the relative importance of features associated with the options was estimated in a point-allocation exercise. Physicians considered two hypothetical patient profiles when completing the exercises. RESULTS The samples included 200 patients and 200 physicians. Patients generally preferred the administration option with which they had experience. Among patients, 48.5% with previous in-clinic injections 24 hours after chemotherapy preferred this option; 56.8% with previous OBI administration preferred this option. For a clinically compromised patient, 37.5% of physicians preferred an in-clinic injection option; 49.5% preferred the OBI. For a less compromised patient, 55.5% preferred an in-clinic injection option; 28.0% preferred the OBI. Avoiding the need to return to the clinic was chosen most often as the most important treatment feature for patients and physicians. CONCLUSIONS Patients and physicians identified that returning clinic visits for pegfilgrastim administration may be burdensome. A potential solution to mitigate this burden is the OBI, which allows adherence to the labeled use of pegfilgrastim without return visits to the clinic.
Collapse
Affiliation(s)
| | - Brennan Mange
- RTI Health Solutions, Research Triangle Park, NC, USA
| | - Mark A Price
- RTI Health Solutions, Research Triangle Park, NC, USA.
| | | | | | | | | |
Collapse
|
17
|
Rosselet PO, Gómez F, Mange B, Savary M, Grigoriu D. [Sphenoid sinusitis and panhypopituitarism]. Schweiz Med Wochenschr 1984; 114:1340-2. [PMID: 6387901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The case is reported of a patient who presented with panhypopituitarism simultaneously with sphenoid sinusitis due to Aspergillus fumigatus. Despite the absence of radiologically demonstrable suprasellar or intrasellar lesions, and without visible bone destruction, the authors conclude on the possibility of a pituitary lesion by contiguity. The pathogenic mechanisms are discussed.
Collapse
|
18
|
|